Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Nuvation Bio Inc. Class A Common Stock (NUVB) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance

Nuvation Bio Inc. Class A Common StockTrade
State Street SPDR S&P Biotech ETFTrade

Price performance (Past 24H)

Key statistics

Nuvation Bio Inc. Class A Common Stock vs State Street SPDR S&P Biotech ETF — how do they compare? Nuvation Bio Inc. Class A Common Stock trades at $5.22 (market cap $1.74B), while State Street SPDR S&P Biotech ETF trades at $149.93 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 5.8× Nuvation Bio Inc. Class A Common Stock's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Nuvation Bio Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nuvation Bio Inc. Class A Common Stock for 0 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.

NUVBXBI
Market Cap
$1.74B$10.11B
Volume
9,289,61912,903,266
Sector
HealthBroad Market / Factor
52-Week High
$9.54$169.55
52-Week Low
$3.41$104.99
Typical Hold Time
0 Days37 Days
Enterprise Value
$1.33B—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Nuvation Bio Inc. Class A Common Stock

No Aura AI signal available yet.

State Street SPDR S&P Biotech ETF

XBI trades at $150.23, down 0.44% on the day, with a bearish technical signal driven by moving averages and oscillators. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts. Recent news highlights sector optimism from cancer vaccine breakthroughs and improved capital access, though the ETF carries higher volatility than broader healthcare funds.

The outlook is mixed: strong sector tailwinds from innovation and consolidation support growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst sentiment is neutral with 100% hold ratings, suggesting cautious optimism amid technical bearishness.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

NUVB
100% Buy0% Sell
Avg holding period · 0 Days
XBI
100% Buy0% Sell
Avg holding period · 37 Days

About Nuvation Bio Inc. Class A Common Stock

Nuvation Bio Inc. is a biopharmaceutical company focused on oncology, developing novel cancer treatments including taletrectinib (marketed as IBTROZI), a ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor.

Read more on NUVB →

About State Street SPDR S&P Biotech ETF

XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.

Read more on XBI →